AliveX
The AI engine Fit Assessment
BetaAliveX effectively utilizes machine learning for pattern discovery and therapeutic expansion, with a strong focus on biomarker identification.
Blurb
Application of artificial intelligence, multi-omics data, and digital disease models to enable the next era of target & biomarker R&D.
HQ Location
Australia
Founded
2019
Employees
51 - 200
Total funding raised
Not available
Last Funding Event
Seed, June 22, 2021
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Biomarker Identification
Developer of an AI-driven immunology platform designed to focus on biomarker discovery. The company's platform combines multi-omics data, AI, and computational biology to decode the human immune system, enabling immunologists, molecular biologists, and clinical experts to solve the most pressing clinical challenges, and transform life sciences research and develop diagnostics.